Closing the innovation gap: PAREA founder writes on advancing psychedelic therapy and medicines in EU mental health care

Written By Guest User

The EU is currently revising its pharmaceutical legislation, the first revision in 20 years. This presents a significant opportunity to focus on mental health innovation and realign our healthcare innovation priorities to more effectively address the unmet needs in mental health care.

For further insights, read PAREA’s Founder article “Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care,” published in Open Access Government.


Guest User
Previous

PAREA partners for Bio-Neuroscience Summit
Next

Blossom highlights PAREA talk at on the challenges to widespread access